Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Venus Healthcare Homes is exporting its integrated care-village model to Malaysia and across ASEAN, where demographic aging is compressing into a single decade—a timeline that demands infrastructure built for population-wide health maintenance rather than crisis management. The model positions healthy aging as an economic asset only when care systems reach beyond affluent populations to keep ordinary older people well and community-connected.
Aging compromises the brain's ability to flexibly coordinate posture and balance through a paradoxical mechanism: central neural networks become overly rigid while peripheral sensory input becomes disconnected from motor control. This fundamental loss of adaptive capacity directly undermines fall prevention and movement quality across the lifespan.
Tim Maupin's film explores the ethical and personal dimensions of rejuvenation technology arriving before universal access, examining what happens when life-extension therapies can save some but not others. The narrative anchors longevity science in the lived human experience of aging parents and the institutional barriers that determine who benefits from breakthrough interventions.
Alterity Therapeutics secured a US composition-of-matter patent for ATH434 extending exclusivity to 2045, protecting the exact crystalline form used in clinical trials for Multiple System Atrophy. The patent strengthens the company's negotiating position for partnerships and creates a commercial foundation for expanding development into Parkinson's disease, a substantially larger patient population.
Oligomerix appointed an experienced pharmaceutical executive as interim CEO to advance its Alzheimer's pipeline, specifically its lead candidate OLX 07010, which demonstrated tau reduction in preclinical models and acceptable safety in Phase 1a human studies. The leadership transition positions the company to move from discovery into clinical-stage development of tau-targeting therapeutics.
Family caregivers of dementia patients in rural and remote areas experience significantly higher burden than urban counterparts, driven by isolation, limited access to support services, and financial strain. Understanding these regional disparities is essential for designing interventions that address the specific stressors affecting caregiver health and longevity.
A monthly research digest covering advances in aging biology, from lifespan extension through amino acid restriction to cellular senescence mechanisms and metabolic interventions. The findings underscore that aging is not a single process but a collection of interconnected cellular and systemic dysfunctions that require multi-targeted approaches for meaningful intervention.
Canada's advisory committee recommended public funding for Leqembi (aducanumab), an anti-amyloid monoclonal antibody for early Alzheimer's disease, following US authorization of subcutaneous administration routes. This decision expands access to a disease-modifying therapy targeting amyloid pathology in mild cognitive impairment and mild dementia stages, with potential to influence provincial funding and treatment delivery infrastructure across Canada.
Oligomerix appointed Dr. Cara Cassino as interim CEO to advance OLX-07010, an oral small-molecule candidate designed to prevent tau protein accumulation in Alzheimer's disease. The compound completed Phase 1a with favorable safety and is moving toward expanded clinical testing in Alzheimer's and related tauopathies.
NeuroSense has restructured its PrimeC development strategy for ALS to accelerate regulatory submission while reducing costs, incorporating AI analysis of prior Phase 2b data, a direct comparison trial against edaravone, and an optimized Phase 3 study designed for earlier disease stages. The approach leverages biomarker findings suggesting PrimeC modulates extracellular vesicle-associated TDP-43 and slows functional decline.
Researchers developed J-HAS, a wearable-derived metric using Wasserstein distance mathematics to quantify sleep-activity regularity patterns. The metric correlates with biological aging markers and predicts healthspan trajectory, offering a measurable window into whether daily rhythms support or undermine longevity.
Mission Therapeutics and NeuraLight are integrating eye-movement-derived biomarkers into a Phase Ib trial of MTX325, a USP30 inhibitor designed to restore mitochondrial quality control in Parkinson's disease. This partnership aims to detect functional neural changes that conventional clinical assessments may miss, providing objective measures of whether restoring cellular energy production capacity translates to clinical benefit.